Biodelivery Sciences International (MM) (NASDAQ:BDSIW)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Biodelivery Sciences International (MM) Charts. Click Here for more Biodelivery Sciences International (MM) Charts.](/p.php?pid=staticchart&s=N%5EBDSIW&p=8&t=15)
BioDelivery Sciences International, Inc. (NASDAQ:BDSI,
BDSIW), a specialty pharmaceutical company, announced today that it
has consummated its public offering of 4,400,000 shares of common
stock, resulting in gross proceeds of $8,800,000 million to the
company. The public price per share for the offering was $2.00.
The offering was underwritten by Ferris, Baker Watts Incorporated,
Maxim Group LLC and GunnAllen Financial, Inc. The underwriters have
been granted an option to purchase up to an additional 660,000 shares
of common stock from BDSI to cover over-allotments. If the over
allotment option is exercised, of which no assurance can be given, the
additional shares will also be sold at $2.00 per share and will result
in additional gross proceeds to BDSI of up to $1,320,000.
This communication shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of any
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful.
BioDelivery Sciences International, Inc. is a specialty
biopharmaceutical company that is exploiting its licensed and patented
drug delivery technologies to develop and commercialize, either on its
own or in partnerships with third parties, clinically-significant new
formulations of proven therapeutics targeted at "acute" treatment
opportunities such as pain, anxiety, nausea and vomiting and
infections. The company's drug delivery technologies include: (i) the
patented Bioral(R) nanocochleate technology, designed for a
potentially broad base of applications, and (ii) the patented BEMA(TM)
(transmucosal or mouth) drug delivery technology. The company's
headquarters are located in Morrisville, North Carolina and its
principal laboratory is located in Newark, New Jersey.
Note: Except for the historical information contained herein, this
press release contains, among other things, certain forward-looking
statements, within the meaning of the Private Securities Litigation
Reform Act of 1995, that involve risks and uncertainties. Such
statement may include, without limitation, statements with respect to
the Company's plans, objectives, expectations and intentions and other
statements identified by words such as "may", "could", "would",
"should", "believes", "expects", "anticipates", "estimates",
"intends", "plans" or similar expressions. These statements are based
upon the current beliefs and expectations of the Company's management
and are subject to significant risks and uncertainties, including
those detailed in the Company's filings with the Securities and
Exchange Commission. Actual results may differ from those set forth in
the forward-looking statements. These forward-looking statements
involve certain risks and uncertainties that are subject to change
based on various factors (many of which are beyond the Company's
control).
L.G. Zangani, LLC provides financial public relations service to
the Company. As such L.G. Zangani, LLC and/or its officers, agents and
employees, receives remuneration for public relations and or other
services in the form of monies, capital stock in the Company, warrants
or options to purchase capital in the Company.